Vertex Receivables Turnover vs Operating Margin Analysis

VRTX Stock

USD 397.36 0.81 0.20%

Vertex Pharmaceuticals financial indicator trend analysis is much more than just breaking down Vertex Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vertex Pharmaceuticals is a good investment. Please check the relationship between Vertex Pharmaceuticals Receivables Turnover and its Operating Profit Margin accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Receivables Turnover vs Operating Profit Margin

Receivables Turnover vs Operating Margin Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vertex Pharmaceuticals Receivables Turnover account and Operating Margin. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Vertex Pharmaceuticals' Receivables Turnover and Operating Margin is -0.49. Overlapping area represents the amount of variation of Receivables Turnover that can explain the historical movement of Operating Margin in the same time period over historical financial statements of Vertex Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Vertex Pharmaceuticals' Receivables Turnover and Operating Margin is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Receivables Turnover of Vertex Pharmaceuticals are associated (or correlated) with its Operating Margin. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Margin has no effect on the direction of Receivables Turnover i.e., Vertex Pharmaceuticals' Receivables Turnover and Operating Margin go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Receivables Turnover

Operating Profit Margin

Most indicators from Vertex Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 798.2 M in 2024, whereas Discontinued Operations is likely to drop (861.8 K) in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	6.7B	7.9B	8.6B	9.0B
Total Revenue	7.6B	8.9B	9.8B	10.3B

Gross Profit Total Revenue

Vertex Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Property Plant And Equipment Gross	Net Receivables	Common Stock Total Equity	Common Stock	Other Assets	Long Term Debt
Total Assets		0.37	0.96	0.98	1.0	0.88	-0.98	0.94	0.99	0.99	0.89	0.99	0.21	0.58	0.45	0.59	0.99	1.0	-0.06	0.98	0.94	0.99	0.36	0.37	0.86	0.04
Short Long Term Debt Total	0.37		0.31	0.35	0.34	0.64	-0.25	0.13	0.32	0.41	0.2	0.34	0.6	0.8	0.08	0.7	0.49	0.35	0.3	0.44	0.43	0.32	0.7	0.7	0.24	0.65
Other Current Liab	0.96	0.31		0.99	0.96	0.81	-0.92	0.94	0.93	0.96	0.82	0.94	0.11	0.47	0.54	0.48	0.94	0.95	-0.16	0.95	0.89	0.94	0.28	0.29	0.77	0.04
Total Current Liabilities	0.98	0.35	0.99		0.98	0.84	-0.94	0.94	0.95	0.98	0.84	0.96	0.17	0.51	0.57	0.54	0.97	0.97	-0.09	0.97	0.91	0.97	0.33	0.34	0.82	0.03
Total Stockholder Equity	1.0	0.34	0.96	0.98		0.88	-0.98	0.95	0.99	0.99	0.89	0.99	0.18	0.55	0.44	0.57	0.98	1.0	-0.08	0.97	0.94	0.99	0.34	0.35	0.87	0.01
Property Plant And Equipment Net	0.88	0.64	0.81	0.84	0.88		-0.83	0.72	0.86	0.88	0.76	0.88	0.46	0.79	0.2	0.8	0.91	0.88	-0.07	0.86	0.91	0.86	0.61	0.61	0.75	0.26
Net Debt	-0.98	-0.25	-0.92	-0.94	-0.98	-0.83		-0.94	-1.0	-0.94	-0.96	-0.99	-0.2	-0.55	-0.38	-0.54	-0.96	-0.99	0.06	-0.95	-0.94	-0.99	-0.33	-0.34	-0.84	0.0
Retained Earnings	0.94	0.13	0.94	0.94	0.95	0.72	-0.94		0.94	0.93	0.84	0.93	-0.1	0.34	0.47	0.29	0.89	0.94	-0.12	0.93	0.88	0.93	0.06	0.07	0.79	-0.14
Cash	0.99	0.32	0.93	0.95	0.99	0.86	-1.0	0.94		0.96	0.95	1.0	0.21	0.58	0.39	0.57	0.97	1.0	-0.05	0.96	0.95	0.99	0.35	0.36	0.84	0.02
Non Current Assets Total	0.99	0.41	0.96	0.98	0.99	0.88	-0.94	0.93	0.96		0.83	0.96	0.19	0.54	0.49	0.59	0.98	0.97	-0.06	0.96	0.91	0.97	0.36	0.37	0.88	0.04
Non Currrent Assets Other	0.89	0.2	0.82	0.84	0.89	0.76	-0.96	0.84	0.95	0.83		0.94	0.27	0.58	0.25	0.54	0.88	0.92	-0.04	0.86	0.9	0.94	0.35	0.36	0.75	0.03
Cash And Short Term Investments	0.99	0.34	0.94	0.96	0.99	0.88	-0.99	0.93	1.0	0.96	0.94		0.23	0.6	0.4	0.59	0.98	1.0	-0.07	0.97	0.95	0.99	0.37	0.38	0.85	0.04
Common Stock Shares Outstanding	0.21	0.6	0.11	0.17	0.18	0.46	-0.2	-0.1	0.21	0.19	0.27	0.23		0.65	-0.01	0.82	0.3	0.22	0.18	0.2	0.27	0.23	0.97	0.97	0.23	0.6
Non Current Liabilities Total	0.58	0.8	0.47	0.51	0.55	0.79	-0.55	0.34	0.58	0.54	0.58	0.6	0.65		-0.11	0.79	0.67	0.59	0.1	0.61	0.66	0.57	0.72	0.73	0.39	0.53
Other Current Assets	0.45	0.08	0.54	0.57	0.44	0.2	-0.38	0.47	0.39	0.49	0.25	0.4	-0.01	-0.11		0.13	0.46	0.43	0.27	0.47	0.29	0.43	0.1	0.1	0.33	-0.2
Other Stockholder Equity	0.59	0.7	0.48	0.54	0.57	0.8	-0.54	0.29	0.57	0.59	0.54	0.59	0.82	0.79	0.13		0.66	0.58	0.07	0.55	0.58	0.59	0.87	0.88	0.59	0.41
Total Liab	0.99	0.49	0.94	0.97	0.98	0.91	-0.96	0.89	0.97	0.98	0.88	0.98	0.3	0.67	0.46	0.66		0.99	0.01	0.98	0.94	0.98	0.46	0.47	0.83	0.12
Total Current Assets	1.0	0.35	0.95	0.97	1.0	0.88	-0.99	0.94	1.0	0.97	0.92	1.0	0.22	0.59	0.43	0.58	0.99		-0.06	0.98	0.95	0.99	0.36	0.37	0.85	0.03
Short Term Debt	-0.06	0.3	-0.16	-0.09	-0.08	-0.07	0.06	-0.12	-0.05	-0.06	-0.04	-0.07	0.18	0.1	0.27	0.07	0.01	-0.06		-0.02	-0.04	-0.04	0.18	0.18	-0.18	-0.15
Accounts Payable	0.98	0.44	0.95	0.97	0.97	0.86	-0.95	0.93	0.96	0.96	0.86	0.97	0.2	0.61	0.47	0.55	0.98	0.98	-0.02		0.94	0.96	0.37	0.38	0.81	0.1
Property Plant And Equipment Gross	0.94	0.43	0.89	0.91	0.94	0.91	-0.94	0.88	0.95	0.91	0.9	0.95	0.27	0.66	0.29	0.58	0.94	0.95	-0.04	0.94		0.95	0.4	0.41	0.78	0.11
Net Receivables	0.99	0.32	0.94	0.97	0.99	0.86	-0.99	0.93	0.99	0.97	0.94	0.99	0.23	0.57	0.43	0.59	0.98	0.99	-0.04	0.96	0.95		0.36	0.37	0.86	0.02
Common Stock Total Equity	0.36	0.7	0.28	0.33	0.34	0.61	-0.33	0.06	0.35	0.36	0.35	0.37	0.97	0.72	0.1	0.87	0.46	0.36	0.18	0.37	0.4	0.36		1.0	0.34	0.61
Common Stock	0.37	0.7	0.29	0.34	0.35	0.61	-0.34	0.07	0.36	0.37	0.36	0.38	0.97	0.73	0.1	0.88	0.47	0.37	0.18	0.38	0.41	0.37	1.0		0.35	0.6
Other Assets	0.86	0.24	0.77	0.82	0.87	0.75	-0.84	0.79	0.84	0.88	0.75	0.85	0.23	0.39	0.33	0.59	0.83	0.85	-0.18	0.81	0.78	0.86	0.34	0.35		0.01
Long Term Debt	0.04	0.65	0.04	0.03	0.01	0.26	0.0	-0.14	0.02	0.04	0.03	0.04	0.6	0.53	-0.2	0.41	0.12	0.03	-0.15	0.1	0.11	0.02	0.61	0.6	0.01

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Short Long Term Debt Total	577.4M	581.5M	556.7M	561M	808.4M	848.8M
Other Current Liab	1.0B	1.2B	1.5B	1.9B	2.9B	3.1B
Total Current Liabilities	1.2B	1.6B	1.9B	2.4B	3.5B	3.7B
Total Stockholder Equity	6.1B	8.7B	10.1B	13.9B	17.6B	18.5B
Property Plant And Equipment Net	745.1M	958.5M	1.1B	1.1B	1.5B	1.5B
Net Debt	(2.5B)	(5.4B)	(6.2B)	(9.9B)	(9.6B)	(9.1B)
Retained Earnings	(1.9B)	858.7M	3.2B	6.5B	10.1B	10.6B
Cash	3.1B	6.0B	6.8B	10.5B	10.4B	10.9B
Non Current Assets Total	3.7B	3.9B	4.4B	5.5B	8.6B	9.0B
Non Currrent Assets Other	326.9M	662.5M	901.1M	1.3B	796.7M	836.5M
Cash And Short Term Investments	3.8B	6.7B	7.5B	10.8B	11.2B	11.8B
Common Stock Shares Outstanding	260.7M	263.4M	259.9M	259.1M	260.5M	153.1M
Liabilities And Stockholders Equity	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Non Current Liabilities Total	1.0B	1.5B	1.5B	1.8B	1.6B	1.7B
Other Current Assets	213.5M	308.4M	187.2M	74.4M	620.5M	651.5M
Other Stockholder Equity	7.9B	7.9B	6.9B	7.4B	7.4B	7.8B
Total Liab	2.2B	3.1B	3.3B	4.2B	5.1B	5.4B
Total Current Assets	4.6B	7.8B	9.0B	12.7B	14.1B	14.9B
Short Term Debt	30.3M	42.4M	46.9M	89.4M	83.7M	51.0M
Accounts Payable	87.6M	155.1M	195M	303.9M	364.9M	383.1M
Property Plant And Equipment Gross	745.1M	958.5M	2.3B	2.5B	2.6B	2.8B
Accumulated Other Comprehensive Income	(2.0M)	(68.5M)	15.9M	800K	(14.3M)	(13.6M)
Net Receivables	633.5M	885.4M	1.1B	1.4B	1.6B	1.6B
Common Stock Total Equity	2.6M	2.6M	2.5M	2.6M	3.0M	1.9M
Common Stock	2.6M	2.6M	2.5M	2.6M	3.0M	2.0M
Other Assets	1.2B	587.0M	986.9M	1.4B	1.6B	1.7B
Short Term Investments	699.0M	670.7M	729.9M	274.5M	849.2M	579.6M
Property Plant Equipment	833.3M	958.5M	1.1B	1.5B	1.7B	1.8B
Other Liab	275.5M	923.4M	902.2M	685.8M	788.7M	828.1M
Current Deferred Revenue	62.3M	191.5M	171.7M	159.6M	170.3M	118.8M
Inventory	167.5M	280.8M	353.1M	460.6M	738.8M	775.7M
Net Tangible Assets	4.7B	7.3B	8.7B	12.2B	14.1B	14.8B
Retained Earnings Total Equity	(1.9B)	858.7M	3.2B	6.5B	7.5B	7.9B
Long Term Debt Total	583.9M	581.6M	538.6M	539.0M	619.9M	632.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

LTC	Litecoin
STETH	Staked Ether
LINK	Chainlink

When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:

How To Invest In Vertex

Details

Is Vertex Stock a good investment?

Details

What is Vertex Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Transaction History View history of all your transactions and understand their impact on performance

Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.181

Earnings Share

13.88

Revenue Per Share

38.297

Quarterly Revenue Growth

0.093

Return On Assets

0.1317

The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Receivables Turnover vs Operating Margin Analysis

Receivables Turnover vs Operating Profit Margin

Receivables Turnover vs Operating Margin Correlation Analysis

Correlation Coefficient

Receivables Turnover

Operating Profit Margin

Vertex Pharmaceuticals fundamental ratios Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Vertex Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Net Receivables	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets